期刊
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
卷 5, 期 7, 页码 987-996出版社
JOHN WILEY & SONS LTD
DOI: 10.1177/2050640617695698
关键词
Hepatocellular carcinoma; renin-angiotensin system; angiotensin-converting enzyme inhibitor; angiotensin II receptor blocker; sorafenib
资金
- Erwin-Schroedinger Fellowship
- Austrian Science Fund (FWF) [J 3747-B28]
- German Cancer Aid [DKH 110989]
- Volkswagen Foundation
- NIH [P01-CA080124]
Background: Inhibition of the renin-angiotensin system (RAS) was associated with longer survival in patients with different solid malignancies. Objective: The objective of this study was to investigate the effect of RAS inhibitor (RASi) treatment (angiotensin-converting enzyme inhibitors or angiotensin-II-receptor blockers) on survival of patients with hepatocellular carcinoma (HCC). Methods: Patients diagnosed with HCC and Child-Pugh A between 1992 and 2013 who received sorafenib, experimental therapy, or best supportive care were eligible for the Vienna cohort. The Mainz cohort included patients with HCC and Child-Pugh A who received sorafenib treatment between 2007 and 2016. The association between RASi and overall survival (OS) was evaluated in univariate and multivariate analyses. Results: In the Vienna cohort, 43 of 156 patients received RASi for hypertension. RASi treatment was associated with longer OS (11.9 vs. 6.8 months (mo); p=0.014) and remained a significant prognostic factor upon multivariate analysis (HR=0.6; 95% CI 0.4-0.9; p=0.011). In subgroup analysis, patients treated with sorafenib plus RASi had better median OS (19.5mo) compared to those treated with either sorafenib (10.9mo) or RASi (9.7mo) alone (p=0.043). The beneficial effect of RASi on survival was confirmed in the Mainz cohort (n=76). Conclusion: RAS inhibition is associated with longer survival in HCC patients with Child-Pugh class A.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据